Osmind

Osmind is the platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science.

The Osmind treatment platform is currently used by leading interventional mental health practices to safely administer, monitor, and analyze the use of TMS, ECT, ketamine, SPRAVATO®, and psychedelic medicine for people living with moderate to severe mental health conditions. The core EHR technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients.

Research from our platform is already helping to set new standards for mental health interventions. In the largest published real-world analysis of ketamine infusion therapy (KIT), we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022).

Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.

Come join us for an incredible amount of autonomy and ownership at a fast-growing startup working on one of the world's biggest problems.